PUBLIC COMPANY
save$SLNSilence Therapeutics plc
$SLNLondon, GBupdated 3mo ago
Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase2Study to Assess SLN124 in Patients With Polycythemia Vera
- phase2Evaluate SLN360 in Participants With Elevated Lipoprotein(a) at High Risk of Atherosclerotic Cardiovascular Disease Events
- phase1Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a)
- phase1A Study Investigate the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Response of SLN124 in Adults With Alpha/Beta-thalassaemia and Very Low- and Low-risk Myelodysplastic Syndrome
🐶 Hiring Signal
News
- STAT+: Pharmalittle: We’re reading about a Novartis heart drug, BIO fighting a Trump program, and moreNovartis is largely abandoning a drug once considered a potential blockbuster after a study found it had little promise for preventing heart attacks and deathsstat · 7d ago
- This week in charts: a big year for RNAi developersThe latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.biopharma_dive · 24d ago
- STAT+: Roche continues to look to China for new drugsChina's Hansoh Pharmaceutical Group has announced that it struck a massive deal with Roche to develop a portfolio of antibody-drug conjugates.stat · 27d ago
- Merck KGaA makes noise in hematology with $1.1B Silence buySilence Therapeutics’ lead siRNA asset for the rare blood cancer polycythemia vera has been earning analyst raves in a tight race to challenge Takeda in a potential $2 billion market.biospace · 28d ago
- Merck KGaA bets on RNAi with $1.3B Silence buyoutThe acquisition gives the German company a promising blood disorder medicine that passed a Phase 2 test and could threaten a Takeda drug.biopharma_dive · 28d ago
- Merck KGaA to buy Silence Therapeutics and its siRNA pipeline for $1.3BGermany's Merck KGaA agreed to buy UK drug developer Silence Therapeutics for $1.3 billion, building out its work in rare and specialty diseases using genetic medicines. Silence is developing the s…endpoints · 28d ago
- Disc’s rebuffed rare disease drug sets up FDA redo after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Disc’s rebuffed rare blood disease drug sets up FDA re-do after ‘clean’ Phase 3 sweepDisc Medicine’s bitopertin—rejected by the FDA in February—significantly reduced levels of a key disease biomarker and significantly increased the time patients with erythropoietic protoporphyria w…biospace · 29d ago
- Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer winGermany’s Merck KGaA has picked up Silence Therapeutics to the tune of $1.3 billion in the wake of the British biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.fiercebiotech · 29d ago
- Recon: German Merck acquires Silence Therapeutics for $1.3B; China's Hansoh Pharma strikes $15B drug deal with RocheWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 29d ago
Data sources
last refreshed 7m ago
Found something off?
comments(0)
5-min edit window · permanent after that